Research
Scientific articles on peptide research, documentation, purity, and traceability.
Alpha Research
Trends
Media Attention and Peptide Research Integrity: Distinguishing Clinical Evidence from Anecdote in Public Discourse
Viral attention to peptide compounds frequently precedes rigorous clinical data; researchers and clinicians must apply structured evidence appraisal frameworks to evaluate claims circulating in lay and professional media.
Alpha Research
research trends
2026 Research Priorities: GLP-1/GIP Triple Agonists, Mitochondria-Targeting Peptides, and Telomerase Activators
Review of the three peptide research priorities for 2026: GLP-1R/GIP-R/GCG-R triple agonism (Retatrutide, AMG 133, Mazdutide), mitochondria-targeting peptides (SS-31/Elamipretide, SLU-PP-332), and telomerase activators (Epitalon) with critical evidence assessment.
Alpha Research
Science
Translational Peptide Research: From Preclinical Models to Phase 3 Trials — Timeline, Barriers, and Active Development Programmes
Analysis of the translational peptide pipeline: typical IND-to-approval development timeline (8-15 years), key barriers (oral bioavailability, serum stability, immunogenicity), and active development programmes 2025-2026.
Alpha Research
Science
FDA Regulatory Framework for Research Peptides in 2026: 503A/503B Compounding, GLP-1 Scheduling, and Research-Use Documentation
Analysis of FDA's regulatory framework for research peptides in 2026: 503A/503B designations, the GLP-1R agonist transition from Candidate List to Category 1, and documentation requirements for research distributors.
Alpha Research
Longevity
Longevity-Associated Peptides in 2026 Research: Telomerase Activation, Senolytic Mechanisms, and NAD+ Biology
Review of peptides with preclinical evidence across multiple aging pathways: Epitalon and TERT activation, SS-31 and mitochondrial preservation, BPC-157 and senescence reduction, and the role of NAD+ in SIRT6-mediated telomeric maintenance.
Alpha Research
Metabolism
Exercise-Mimetic Compounds: ERR Agonism (SLU-PP-332), AMPK Activation, and Metabolic Reprogramming Research
SLU-PP-332 functions as a pan-ERR agonist activating ERRα/β/γ, mimicking endurance exercise adaptations via PGC-1α, fatty acid oxidation, and mitochondrial biogenesis in preclinical models.
Alpha Research
Metabolism
GLP-1 Receptor Agonism: From Incretin Biology to Dual/Triple Agonist Development — Receptor Pharmacology and Clinical Research Outcomes
Class B GPCR structural pharmacology of GLP-1R: cryo-EM resolved Gαs engagement mechanism, cAMP EC₅₀ in MIN6 β-cells, depot-specific GLP-1R/GIP-R expression asymmetry in VAT vs SAT, super-additive GSIS with tirzepatide, β-arrestin recruitment BRET data, and VAT reduction quantification in DIO models with GLP-1R/GIP-R/GCG-R triple agonism.
Alpha Research
cellular longevity
The GLOW Formulation: GHK-Cu + TB-500 + BPC-157 — Mechanistic Rationale for Synergistic Angiogenic and Collagen Remodeling Research
Alpha Nordisk GLOW (GHK-Cu · TB-500 · BPC-157 blend, 70mg) is a research formulation whose components address mechanistically distinct but convergent nodes in angiogenesis, ECM remodeling, and dermal repair biology. This article documents the individual pharmacology and evidence base for combination activity in preclinical models of vascular and connective tissue research.
Alpha Research
Fundamentals
2026 Research Frontiers: GLP-1/GIP Triple Agonists, Mitochondrial Peptides, and Senolytic Peptide Agents
Analysis of the three most active areas of peptide research in 2026: triple incretin receptor agonism (GLP-1R/GIPR/GCGR) with retatrutide as the clinical prototype, mitochondrial peptidomics with elamipretide and MOTS-c as biogenesis agents, and senolytic peptides based on FOXO4-DRI sequences for senescent cell elimination.